Molecules and methods for modulating complement component

Details for Australian Patent Application No. 2008320820 (hide)

Owner Novartis AG

Inventors Keating, Mark Taylor; Splawski, Igor; Milik, Mariusz; Klickstein, Lloyd B.; Zhao, Kehao; Kim, Yong-In; Mikhailov, Dmitri; Etemad-Gilbertson, Bijan; Guild, Braydon Charles; Roguska, Michael

Agent Davies Collison Cave

Pub. Number AU-A-2008320820

PCT Pub. Number WO2009/056631

Priority 60/984,951 02.11.07 US

Filing date 31 October 2008

Wipo publication date 7 May 2009

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 7/00 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

Event Publications

15 April 2010 PCT application entered the National Phase

  PCT publication WO2009/056631 Priority application(s): WO2009/056631

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008320821-Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

2008320818-Fish vaccine